Razoxane

SKU: orb1305273

Description

Razoxane is a small molecule antimitotic and immunosuppressive agent. It has been utilized in research to study cell cycle inhibition and immune modulation, with applications in both in vitro cellular assays and in vivo experimental models.

Research Area

Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 21416-67-1
• MW: 268.27
• Purity: 99.42% (May vary between batches)
• Formula: C₁₁H₁₆N₄O₄
• SMILES: CC(CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
• Target: Topoisomerase
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (7.46 mM);DMSO:60 mg/mL (223.66 mM)

Bioactivity

• In Vivo:
  This tumor model is characterized by osteoid formation and spontaneous metastasization to lungs, kidneys and lymph nodes. Razoxane given intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation (30 mg/kg or 10 mg/kg per day) resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor. Early treatment with razoxane (30 mg/kg i.p. from day -2 to +14) showed a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Whereas 59.9 per cent of the total sectional area of the lungs in the control animals was covered by osteosarcoma metastases, only 3.4 per cent and 26.1 per cent respectively was affected in the early and late razoxane treatment groups. Toxic side-effects of these treatment schedules were reversible diffuse alopecia, but no retardation of body weight gain.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, ICRF 159, ICRF159, ICRF-159, Inhibitor, renal cell carcinoma, Topo II, Topoisomerase, Topoisomerase II Inhibitor, RCC, Razoxane

Compound Identifiers

PubChem CID

30623